证券代码：300595 证券简称：欧普康视 公告编号：2025-097 欧普康视科技股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 网络投票时间：通过深圳证券交易所交易系统网络投票时间为 12 月 25 日 9:15-9:25，9:30-11:30 和 13:00-15:00；深圳证券交易所互联网投票系统投票 时间为 12 月 25 日 9:15 至 15:00。 2、会议召开地点：合肥市高新技术开发区望江西路 4899 号 2 号楼二楼会议 室。 1、本次股东会召开期间无否决提案的情况； 2、本次股东会未出现涉及变更以往股东会已通过决议的情况。 一、会议召开和出席情况 1、会议召开时间： 现场会议时间：2025 年 12 月 25 日 14:45 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：董事会。 5、会议主持人：公司董事长陶悦群先生因其他工作事项不能主持本次会议， 经半数以上董事推举，由公司董事施贤梅女士主持。 6、本次股东会召集、召开与表决程序符合《公司法》《上市公 ...

Core Viewpoint - Hefei Oupu Sanyang Technology Co., Ltd. has changed its registration status from active to cancellation, following the issuance of a simple cancellation announcement [1]. Company Information - The company was established on August 18, 2023, with a registered capital of 30 million RMB and a paid-in capital of 5 million RMB [2]. - The legal representative of the company is Sun Yongjian [2]. - The company is classified as a limited liability company (natural person investment or holding) and is located in Hefei High-tech Industrial Development Zone, Anhui Province [2]. - The business scope includes sales of Class I and Class II medical devices, daily necessities, and other related services [2]. Ownership Structure - The company is jointly held by Oupu Kangshi, Hefei Sanziyang Network Technology Co., Ltd., and Zhao Chunsheng [2].

Group 1 - The core point of the article is that Opcon Vision (300595) reported a total of 61,914 shareholders as of December 19, 2025 [1]

Group 1 - The company, Opcon Vision (300595.SZ), has invested in a fund that is developing an ophthalmic surgical robot, which is currently in the clinical trial phase [1] - The company has also invested in a fund that is developing a companion robot, which is in the prototype development and validation stage [1] - Both products have not yet been officially launched [1]

Core Viewpoint - The company has received clinical trial approval for its product, Pilocarpine Hydrochloride Eye Drops, but it is too early to discuss its market launch and sales channels [2] Group 1 - The product, Pilocarpine Hydrochloride Eye Drops, has just received clinical trial approval [2] - The company indicated that the progress of the drug will be disclosed according to regulations [2]

Group 1 - The core viewpoint of the article is that the company Oupai Kangshi (300595.SZ) has not yet implemented smart medical technology in its operations [1] Group 2 - Investors are inquiring about the future development layout of Shangyue Qicheng Hospital Management Co., Ltd. in AI and smart medical sectors [1] - The company has not provided any updates or applications regarding smart medical technology [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025-096 关于持股5%以上股东部分股份补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）的通知，获悉其 将持有公司部分股份补充质押给招商证券股份有限公司。现将具体情况公告如下： 一、股东股份质押的基本情况 | | 是否为控 | | 占其 | 占公 | | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 本次质押数 | 所持 | 司总 | 是否 | 为补 | 质押 | 质押 | | 质押 | | 名称 | 第一大股 | 量（股） | 股份 | 股本 | 为限 | 充质 | 起始日 | 到期日 | 质权人 | 用途 | | | 东及其一 | | 比例 | 比例 | 售股 | | | | | | | | 致行动人 | | （%） ...

证券日报网讯12月15日，欧普康视（300595）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总人数为61929户。 ...

12月15日，深证成指、创业板指、深证100、创业板50等深市指数样本调整将生效。值得注意的是，被 称为"眼茅"之一的欧普康视（300595）被调出了创业板指数样本股名单。 来源：读创财经 | 调入名单 | | 调出名单 | | | --- | --- | --- | --- | | 证券代码 | 证券简称 | 证券代码 | 证券简称 | | 300100 | 双林股份 | 300070 | 碧水源 | | 300255 | 常山药业 | 300212 | 易华录 | | 300432 | 富临精工 | 300390 | 天华新能 | | 300548 | 长芯博创 | 300595 | 欧普康视 | | 300718 | 长盛轴承 | 300761 | 立华股份 | | 300972 | 万辰集团 | 300776 | 帝尔激光 | | 301200 | 大族数控 | 301029 | 怡合达 | | 301611 | 珂玛科技 | 301267 | 炎魔眼科 | 审读：乔会青 公开资料显示，欧普康视主营业务是眼健康和近视防控技术与服务，公司的主要产品是硬性接触镜类及 其护理产品、硬镜以外的其它视光产品、其 ...

Core Viewpoint - The company is actively investing in innovative medical technologies, specifically in ophthalmic surgical robots and companion robots for children with autism and intellectual disabilities [1] Group 1: Investment in Medical Technology - The company has invested in a fund that supports the development of an ophthalmic surgical robot by Dishi Medical, which is designed for high-precision fundus surgeries and is currently in the clinical trial registration phase [1] - The company also participates in a fund that invests in Harbin Aiside's development of companion robots for children with autism and intellectual disabilities, which are intended to assist teachers during special education training and have completed prototype development [1]